Name: how bacteria outsmart antibiotics
Uploaded: 2026-03-12T13:35:59.000Z
Duration: 1 min 25 s
Channel: JoVE

Staphylococcus aureus 常见于人体皮肤，但它是一种机会性致病菌。耐甲氧西林金黄色葡萄球菌（MRSA）是一种对甲氧西林及大多数其他β-内酰胺类抗生素（如青霉素）具有耐药性的金黄色葡萄球菌。耐甲氧西林金黄色葡萄球菌（MRSA）菌株会改变大多数β-内酰胺类抗生素作用靶点的青霉素结合蛋白（PBPs）。在耐甲氧西林金黄色葡萄球菌（MRSA）菌株中，这种耐药性的产生是由于存在 mecA 基因，该基因编码一种称为 PBP2a 的变异青霉素结合蛋白。这种改变的PBP2a对β-内酰胺类抗生素的结合亲和力较低，使得耐甲氧西林金黄色葡萄球菌（MRSA）即使在这些药物存在的情况下仍能合成其细胞壁。在许多耐甲氧西林金黄色葡萄球菌（MRSA）菌株中，调控 mecA 表达的调节基因 mecI 和 mecR1 是无功能的。这导致 PBP2a 的持续表达以及稳定耐药性的形成。耐甲氧西林金黄色葡萄球菌（MRSA）可能表现出异质性耐药，即仅有一部分细菌群体表达耐药性；也可能表现出均一性耐药，即整个细菌群体均具有耐药性。

耐甲氧西林金黄色葡萄球菌（mrsa）的抗生素耐药机制

Mechanism of Antibiotic Resistance in MRSA

细菌对抗生素的耐药性源于微生物进化出抵抗原本用于杀死它们或抑制其生长的药物的能力，从而使曾经有效的治疗方法失去作用。这一现象由遗传改变和在抗生素暴露下的选择作用驱动，对现代医学构成严重威胁。其机制包括：使药物失活的酶（如β-内酰胺酶）、将抗生素排出菌体的外排泵、改变抗生素作用靶点的突变、药物摄入减少，以及通过水平基因转移获得耐药基因。耐药性可能在&#8239;通过突变新产生，或通过质粒和转座子等可移动遗传元件迅速传播。抗生素的滥用和过度使用所产生的选择压力加速了耐药菌株的出现和扩散。临床上，耐药菌感染更难治疗，通常需要使用毒性更强或价格更高的药物，延长住院时间，增加医疗成本，并导致发病率和死亡率上升。全球估计表明，如果耐药性趋势持续下去，每年将有数百万人死于此类感染。耐甲氧西林金黄色葡萄球菌（MRSA） 耐甲氧西林金黄色葡萄球菌（MRSA）是抗生素耐药性的典型代表。通过SCCmec元件获得mecA基因，S.&#8239;金黄色葡萄球菌产生一种结构改变的青霉素结合蛋白PBP2a，该蛋白不与β-内酰胺类药物结合，从而对青霉素类、头孢菌素类和碳青霉烯类药物产生广泛耐药性。耐甲氧西林金黄色葡萄球菌（MRSA）最初在医院环境中出现（HA-MRSA），随后在社区中出现（CA-MRSA），其传播由基因突变和水平基因转移共同驱动。临床上，MRSA可引起严重的皮肤、软组织、血流及肺炎感染，常使用万古霉素、达托霉素或利奈唑胺进行治疗，但这些替代药物也存在一定的局限性。细菌抗生素耐药性的其他一些例子：耐万古霉素肠球菌（VRE）与耐万古霉素金黄色葡萄球菌（VRSA）&#160; 耐万古霉素的肠球菌通过获得万古霉素抗性基因操纵子（如 vanA）而产生，这些基因已进一步转移至 S.&#8239;金黄色葡萄球菌，导致罕见但危险的耐万古霉素菌株 S.&#8239;aureus 耐万古霉素金黄色葡萄球菌（VRSA）菌株。由于治疗选择有限，VRSA感染难以治疗，尽管其发生率较低，但仍引起严重的临床关注。耐药性 Streptococcus pneumoniae（DRSP）&#160; S.&#8239;pneumoniae 通过青霉素结合蛋白的突变对青霉素产生耐药性，并通过甲基转移酶基因对大环内酯类抗生素产生耐药性。这些变化降低了肺炎、脑膜炎和中耳炎治疗的有效性，因而需要使用更高级别的抗生素，如头孢菌素或氟喹诺酮类药物，但这些药物本身也存在风险。总之，抗生素耐药性通过基因适应和基因交换而演化，对MRSA、VRE/VRSA和DRSP等重要病原体具有显著的临床影响。确保合理使用抗生素、监测耐药模式、实施感染控制以及开发新型治疗手段，对于缓解这一日益严重的公共卫生危机至关重要。

耐甲氧西林金黄色葡萄球菌（MRSA）的抗生素耐药机制

细菌耐药性是指微生物进化出抵抗原本用于杀灭它们或抑制其生长的药物的能力，……

https://cloudfront.jove.com/files/ftp_upload/40835/40835_article_thumb_40835.jpg

mechanism-of-antibiotic-resistance-in-mrsa

Education

教育

JoVE Core

Microbiology

微生物学

Unit

单元

Antimicrobial Agents

抗微生物药物

KEY TERMS AND CONCEPTS

关键术语与概念

MRSA抗生素耐药性机制

how bacteria outsmart antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working.

Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower drug uptake, or from new resistance genes gained through horizontal gene transfer, which is the movement of DNA between organisms.

Resistance may appear through new mutations or spread quickly through mobile genetic elements like plasmids and transposons. Misuse and overuse of antibiotics increase selection pressure, which helps resistant strains survive and spread. This makes antibiotic-resistant infections harder to treat and often forces doctors to use more toxic or more expensive drugs. These infections can also lead to longer hospital stays, higher healthcare costs, and more illness and death.

MRSA, short for methicillin-resistant Staphylococcus aureus, is a well-known example of this process. It acquired the mecA gene through the SCCmec element and makes an altered penicillin-binding protein called PBP2a. Because PBP2a does not bind beta-lactam drugs well, MRSA resists penicillins, cephalosporins, and carbapenems. MRSA first spread in hospitals as HA-MRSA and later in communities as CA-MRSA. It can cause skin, soft-tissue, bloodstream, and pneumonia infections, and it is often treated with vancomycin, daptomycin, or linezolid, although these options have limits.

Other resistant bacteria show the same problem in different forms. Vancomycin-resistant enterococci can gain van genes, such as vanA, and those genes can transfer to S. aureus to create rare but dangerous VRSA strains. Streptococcus pneumoniae can become resistant to penicillin through changes in penicillin-binding proteins and to macrolides through methyltransferase genes. These changes can make pneumonia, meningitis, and otitis media harder to treat and may require higher-tier antibiotics such as cephalosporins or fluoroquinolones.

Antibiotic resistance grows through genetic adaptation and gene exchange. Its impact reaches major pathogens such as MRSA, VRE, VRSA, and drug-resistant S. pneumoniae. Careful antibiotic use, resistance surveillance, infection control, and new treatments are important ways to slow this public health threat.

How Bacteria Outsmart Antibiotics

inhibitors of gram-positive cell wall synthesis

inhibitors-of-gram-positive-cell-wall-synthesis

How Antibiotics Block Bacterial Cell Walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how bacteria become antibiotic resistant, from beta-lactamases and efflux pumps to MRSA, VRE, VRSA, and drug-resistant Streptococcus pneumoniae.

How Bacteria Outsmart Antibiotics | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Bacteria Outsmart Antibiotics

Description

Transcript

Tags